Subscribe
shutterstock_298303490_vonaua
VonaUA / Shutterstock.com
24 March 2020AfricaSarah Morgan

US companies hit hardest by fake medicines: EUIPO, OECD

Companies registered in the US are hit hardest by the trade in counterfeit medicines, which in 2016 reached $4.4 billion, according to a report from the  European Union Intellectual Property Office (EUIPO).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Large-scale probe seizes 10.5m fake medicines
20 December 2022   Operation took place across Europe | Criminal networks are still exploiting opportunities offered by the COVID-19 pandemic.
Big Pharma
Fraudsters will invest heavily in fake COVID-19 vaccine: Europol
1 May 2020   Once a genuine vaccine against COVID-19 has been announced, counterfeiters and fraudsters are likely to invest heavily in offering ineffective counterfeit versions of the vaccine online, according to Europol.
Big Pharma
OECD and Europol issue COVID-19 counterfeits warning
22 April 2020   The COVID-19 pandemic is heightening the dangers posed by the global trade in counterfeit pharmaceutical products, according to the OECD and EUIPO.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Large-scale probe seizes 10.5m fake medicines
20 December 2022   Operation took place across Europe | Criminal networks are still exploiting opportunities offered by the COVID-19 pandemic.
Big Pharma
Fraudsters will invest heavily in fake COVID-19 vaccine: Europol
1 May 2020   Once a genuine vaccine against COVID-19 has been announced, counterfeiters and fraudsters are likely to invest heavily in offering ineffective counterfeit versions of the vaccine online, according to Europol.
Big Pharma
OECD and Europol issue COVID-19 counterfeits warning
22 April 2020   The COVID-19 pandemic is heightening the dangers posed by the global trade in counterfeit pharmaceutical products, according to the OECD and EUIPO.

More on this story

Big Pharma
Large-scale probe seizes 10.5m fake medicines
20 December 2022   Operation took place across Europe | Criminal networks are still exploiting opportunities offered by the COVID-19 pandemic.
Big Pharma
Fraudsters will invest heavily in fake COVID-19 vaccine: Europol
1 May 2020   Once a genuine vaccine against COVID-19 has been announced, counterfeiters and fraudsters are likely to invest heavily in offering ineffective counterfeit versions of the vaccine online, according to Europol.
Big Pharma
OECD and Europol issue COVID-19 counterfeits warning
22 April 2020   The COVID-19 pandemic is heightening the dangers posed by the global trade in counterfeit pharmaceutical products, according to the OECD and EUIPO.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB